Literature DB >> 25368272

Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.

Franco Lumachi1, Giovanni Lo Re2, Renato Tozzoli3, Federica D'Aurizio3, Flavio Facomer3, Giordano B Chiara4, Stefano M M Basso4.   

Abstract

Cholangiocarcinoma is a malignant tumor of the liver arising from the bile duct epithelium, accounting for 10-25% of all primary hepatic cancers. The clinical presentation of this tumor is not specific and the diagnosis of early cholangiocarcinoma is difficult, especially in patients with other biliary diseases. Measurement of serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) are commonly used to monitor response to therapy, but are also useful for confirming the presence of a cholangiocarcinoma. In this setting, other biomarkers have been previously tested, including cytokeratin-19 fragment (CYFRA 21-1) and the matrix metalloproteinase-7 (MMP7). The purpose of this retrospective study was to determine the clinical usefulness of the assay of serum CEA, CA 19-9, CYFRA 21-1 and MMP7, individually and together, as tumor markers for the diagnosis of cholangiocarcinoma. Twenty-four patients (14 men, 10 women, 62.6±8.2 years of age) with histologically-confirmed cholangiocarcinoma (cases) and 25 age- and sex-matched patients with benign liver disease (controls) underwent measurement of these biomarkers. The mean values of all serum markers of patients with cholangiocarcinoma were significantly higher (p<0.01) than that of the controls. No correlation was found between serum tumor markers and total bilirubin, aspartate aminotransferase (AST) and alkaline phosphatase (ALP). The sensitivity, specificity and accuracy were: CEA: 52%, 55%, and 58%; CA 19-9: 74%, 82% and 78%; CYFRA 21-1: 76%, 79% and 78%; MMP7: 78%, 77% and 80%, respectively. The combination of all serum markers afforded 92.0% sensitivity and 96% specificity in detecting cholangiocarcinoma, showing the highest diagnostic accuracy (94%). In conclusion, our preliminary results suggest that the measurement of all four biomarkers together can help in the early detection of cholangiocarcinoma. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  CA 19-9; CEA; CYFRA 21-1; Cholangiocarcinoma; MMP7; diagnosis; serum tumor marker

Mesh:

Substances:

Year:  2014        PMID: 25368272

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

1.  Combination of Praziquantel and Aspirin Minimizes Liver Pathology of Hamster Opisthorchis viverrini Infection Associated Cholangiocarcinoma.

Authors:  Pakkayanee Sudsarn; Thidarut Boonmars; Wipaporn Ruangjirachuporn; Nisana Namwat; Watcharin Loilome; Pranee Sriraj; Ratchadawan Aukkanimart; Wonkchalee Nadchanan; Songsri Jiraporn
Journal:  Pathol Oncol Res       Date:  2015-08-16       Impact factor: 3.201

Review 2.  Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy.

Authors:  Domenico Viterbo; Valerie Gausman; Tamas Gonda
Journal:  World J Gastrointest Endosc       Date:  2016-02-10

3.  Prediction of Multiple Serum Tumor Markers in Hepatolithiasis Complicated with Intrahepatic Cholangiocarcinoma.

Authors:  Hua Zhao; Benliang Lu
Journal:  Cancer Manag Res       Date:  2022-01-19       Impact factor: 3.989

Review 4.  Evaluation of indeterminate biliary strictures.

Authors:  Christopher L Bowlus; Kristin A Olson; M Eric Gershwin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-11-03       Impact factor: 46.802

5.  Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.

Authors:  Gyem Tshering; Palden Wangyel Dorji; Wanna Chaijaroenkul; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2018-04-05       Impact factor: 2.345

6.  Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia.

Authors:  Han Na Suh; Sohee Jun; Ah-Young Oh; Mrinal Srivastava; Sunhye Lee; Cullen M Taniguchi; Songlin Zhang; Won Sup Lee; Junjie Chen; Bum-Joon Park; Jae-Il Park
Journal:  Sci Rep       Date:  2016-12-06       Impact factor: 4.379

Review 7.  Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy.

Authors:  Margaret G Keane; Amar Shah; Stephen P Pereira; Deepak Joshi
Journal:  F1000Res       Date:  2017-09-05

8.  Ceruloplasmin as a prognostic marker in patients with bile duct cancer.

Authors:  In Woong Han; Jin-Young Jang; Wooil Kwon; Taesung Park; Yongkang Kim; Kyoung Bun Lee; Sun-Whe Kim
Journal:  Oncotarget       Date:  2017-04-25

Review 9.  Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Bin Liang; Liansheng Zhong; Qun He; Shaocheng Wang; Zhongcheng Pan; Tianjiao Wang; Yujie Zhao
Journal:  Med Sci Monit       Date:  2015-11-18

10.  Dickkopf-1 expression is associated with tumorigenity and lymphatic metastasis in human hilar cholangiocarcinoma.

Authors:  Xiang-de Shi; Xian-Huan Yu; Wen-Rui Wu; Xiao-Lin Xu; Jie-Yu Wang; Lei-Bo Xu; Rui Zhang; Chao Liu
Journal:  Oncotarget       Date:  2016-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.